IS8293A - Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX - Google Patents

Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Info

Publication number
IS8293A
IS8293A IS8293A IS8293A IS8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A
Authority
IS
Iceland
Prior art keywords
pyrrole
dione derivatives
liver receptor
regulate liver
regulate
Prior art date
Application number
IS8293A
Other languages
English (en)
Icelandic (is)
Inventor
Boström Jonas
Brickmann Kay
Holm Patrik
Sandberg Pernilla
Swanson Marianne
Westerlund Christer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8293A publication Critical patent/IS8293A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IS8293A 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX IS8293A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
IS8293A true IS8293A (is) 2006-02-09

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8293A IS8293A (is) 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Country Status (25)

Country Link
US (1) US7432288B2 (enExample)
EP (1) EP1646626B1 (enExample)
JP (1) JP2007521312A (enExample)
KR (1) KR20060035748A (enExample)
CN (1) CN1823061A (enExample)
AR (1) AR045721A1 (enExample)
AT (1) ATE399777T1 (enExample)
AU (1) AU2004255999B2 (enExample)
BR (1) BRPI0412472A (enExample)
CA (1) CA2532056A1 (enExample)
DE (1) DE602004014773D1 (enExample)
ES (1) ES2308204T3 (enExample)
GB (1) GB0316232D0 (enExample)
IL (1) IL172760A0 (enExample)
IS (1) IS8293A (enExample)
MX (1) MXPA06000414A (enExample)
MY (1) MY135821A (enExample)
NO (1) NO20060081L (enExample)
RU (1) RU2006102130A (enExample)
SA (1) SA04250204B1 (enExample)
TW (1) TW200503691A (enExample)
UA (1) UA82109C2 (enExample)
UY (1) UY28408A1 (enExample)
WO (1) WO2005005417A1 (enExample)
ZA (1) ZA200600222B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513823T1 (de) * 2004-08-17 2011-07-15 Simpson Biotech Co Ltd Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
US7582629B2 (en) 2005-01-10 2009-09-01 Astrazeneca Ab Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
MX2008013477A (es) * 2006-04-28 2008-10-29 Esteve Labor Dr Compuestos biciclicos de tetrahidropirrol.
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
CA2727252A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
AU2011336970A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
EP2646018B1 (en) 2010-12-03 2014-10-22 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4929999A (en) 1998-07-30 2000-02-21 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels
WO2001013916A1 (en) 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
UY28408A1 (es) 2005-02-28
US7432288B2 (en) 2008-10-07
UA82109C2 (uk) 2008-03-11
US20060235015A1 (en) 2006-10-19
SA04250204B1 (ar) 2008-03-23
IL172760A0 (en) 2006-04-10
WO2005005417A1 (en) 2005-01-20
ZA200600222B (en) 2007-04-25
CA2532056A1 (en) 2005-01-20
AR045721A1 (es) 2005-11-09
AU2004255999B2 (en) 2007-08-02
GB0316232D0 (en) 2003-08-13
MY135821A (en) 2008-07-31
KR20060035748A (ko) 2006-04-26
EP1646626B1 (en) 2008-07-02
JP2007521312A (ja) 2007-08-02
RU2006102130A (ru) 2007-08-20
BRPI0412472A (pt) 2006-09-19
AU2004255999A1 (en) 2005-01-20
MXPA06000414A (es) 2006-03-17
ATE399777T1 (de) 2008-07-15
ES2308204T3 (es) 2008-12-01
HK1088320A1 (en) 2006-11-03
NO20060081L (no) 2006-02-08
EP1646626A1 (en) 2006-04-19
TW200503691A (en) 2005-02-01
CN1823061A (zh) 2006-08-23
DE602004014773D1 (de) 2008-08-14

Similar Documents

Publication Publication Date Title
IS8293A (is) Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IS8466A (is) 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka
ZA200700351B (en) Compounds, compositions and methods
ZA200702479B (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IL181408A0 (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
NO20053161D0 (no) Mikrobedrepende sammensetning.
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
NL1030382A1 (nl) Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen.
PL1828154T3 (pl) Pochodne fenylopiperazynometanonu
ZA200700159B (en) Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives
WO2006069159A3 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
EP1811842A4 (en) IMMUNE ACTIVATION COMPOSITIONS BASED ON 3,3'-DIINDOLYLMETHANE
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
DE502005000496D1 (de) Verstellvorrichtung
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
ES1058958Y (es) Mastil perfeccionado.
ES1058483Y (es) Bloque de asientos perfeccionado.
ES1057238Y (es) Buzon perfeccionado.
ITRM20040370A1 (it) Chiusino perfezionato.
ES1058233Y (es) Cambrillon perfeccionado.